Avacta Group Plc/£AVCT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Avacta Group Plc
Avacta Group plc is a UK-based clinical-stage biopharmaceutical company focused on precision oncology therapies. Its core development platform, pre|CISION, uses a peptide linker designed to be cleaved by fibroblast activation protein, a protease associated with many solid tumours, with the aim of releasing cytotoxic payloads in the tumour microenvironment while reducing systemic exposure. The clinical pipeline includes faridoxorubicin (AVA6000), a tumour-activated form of doxorubicin, and AVA6103, a pre|CISION peptide drug conjugate incorporating exatecan. The company also owns the Affimer platform, comprising engineered binding proteins that can be used in therapeutic drug conjugates and diagnostic or research applications. Avacta is headquartered at Imperial College’s White City campus in London and has been transitioning to a pure-play oncology therapeutics business through the divestment of its diagnostics operations.
- Ticker
- £AVCT
- Sector
- Health
- Primary listing
- AIM
- Employees
- 81
- Headquarters
- London, United Kingdom
- Website
- avacta.com
Avacta Group Plc Metrics
BasicAdvanced
£263M
-
-£0.09
-0.11
-
Price and volume
Market cap
£263M
Beta
-0.11
52-week high
£0.92
52-week low
£0.48
Average daily volume
2.2M
Financial strength
Current ratio
0.946
Quick ratio
0.946
Total debt to equity
5.27
Interest coverage (TTM)
-4.54%
Profitability
EBITDA (TTM)
-29.901
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-35,315.93%
Operating margin (TTM)
-26,569.03%
Effective tax rate (TTM)
-3.03%
Management effectiveness
Return on assets (TTM)
-62.36%
Return on equity (TTM)
-1,965.14%
Valuation
Price to revenue (TTM)
2,086.923
Price to book
67.16
Price to tangible book (TTM)
114.07
Price to free cash flow (TTM)
-8.557
Free cash flow yield (TTM)
-11.69%
Free cash flow per share (TTM)
-0.063
Growth
Earnings per share change (TTM)
-45.38%
3-year revenue growth (CAGR)
-80.82%
3-year earnings per share growth (CAGR)
-15.45%
What the Analysts think about Avacta Group Plc
Analyst ratings (Buy, Hold, Sell) for Avacta Group Plc stock.
Analyst projections of the future price of Avacta Group Plc stock.
Bulls say / Bears say
Faridoxorubicin’s Phase 1 study reported median progression-free survival of 11.4 months in a defined group of 32 salivary gland cancer patients, against historical benchmarks of 6–6.7 months. Three partial responses and six minor responses add an early efficacy signal in a rare cancer with limited treatment options. (Avacta Therapeutics)
AVA6103 has shown clinical proof of mechanism: its early pharmacokinetic results matched preclinical modelling, with controlled exatecan release lasting for days. It was well tolerated through the first three dose levels, including a payload dose about 50% above the maximum tolerated dose of conventional exatecan. (Avacta Therapeutics)
The FDA has agreed certain pivotal-trial elements and a regulatory path using Phase 1b data for potential full approval of faridoxorubicin. That clarity could help Avacta advance its lead drug towards a registration strategy, subject to the data supporting it. (Avacta Therapeutics)
Avacta remains dependent on external funding: it reported a £19.0 million net loss for H1 2026 and cash of £10.59 million at the end of August. The October raise extended its stated runway only into Q2 2027, so further financing may be needed before the business can generate meaningful revenue. (Avacta Therapeutics, Avacta Therapeutics)
The £12.5 million October fundraise issued new shares at 68 pence, diluting existing holders, and about £2.5 million of the proceeds was earmarked for a convertible-bond repayment. Repeated reliance on equity to fund trials and debt obligations could weigh on per-share value. (Avacta Therapeutics)
The 11.4-month progression-free survival result comes from a small, selected, non-randomised subset and is compared with historical results, not a control group. Only three of the 32 patients had partial responses, and median overall survival had not been reached, leaving the strength of the clinical benefit uncertain. (Avacta Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2026.
Avacta Group Plc Financial Performance
Revenues and expenses
Avacta Group Plc Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.